Stay updated on LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial
Sign up to get notified when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.

Latest updates to the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page
- Check4 days agoChange DetectedThe page’s footer revision label was updated from v3.5.2 to v3.5.3, reflecting a platform/version update without changing the underlying study details.SummaryDifference0.1%

- Check11 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check40 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check47 days agoChange DetectedRevision label updated to v3.4.3; the previous label v3.4.2 was removed.SummaryDifference0.1%

- Check77 days agoChange DetectedAdministrative updates include revision v3.4.2 and removal of revisions v3.4.1 and a government funding lapse notice; to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check84 days agoChange DetectedA government funding lapse notice has been added to the page, clarifying operational status, and the site revision version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.